• Medtronic invests $US90M in Anteris to support execution of PARADIGM trial
• Underwritten offering of common stock raises additional $US230M
• Collaboration aims to advance clinical science and valve design in TAVR market

Anteris Technologies Global Corp. (Anteris) has announced a $US320 million capital raise, including a $US90 million strategic investment from Medtronic, plc, the world's largest medical technology company. The investment will support the execution of Anteris' global pivotal PARADIGM trial and advance the company towards the global commercialization of its DurAVR® Transcatheter Heart Valve (THV). Anteris and Medtronic are aligned in their commitment to advancing clinical science and valve design in the Transcatheter Aortic Valve Replacement (TAVR) market, while maintaining rigorous standards for durability, hemodynamics, and long-term patient outcomes. The PARADIGM trial is a prospective randomized controlled trial that will evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available TAVRs. The trial has commenced recruitment, with the first patients enrolled and implanted during the fourth quarter of 2025. Anteris is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. The DurAVR® THV is the company's lead product, designed in collaboration with leading interventional cardiologists and cardiac surgeons to treat aortic stenosis.

Anteris expects to use the $US320 million in gross proceeds to execute the global PARADIGM trial and continue investing in research to transform the treatment of aortic stenosis.

The investment from Medtronic and the underwritten public offering position Anteris to continue executing the PARADIGM trial and advancing the commercialization of the DurAVR® THV technology, which has the potential to offer improved valve performance and meet the needs of more aortic stenosis patients.